Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mainz Biomed N.V. - Ordinary Shares (NQ: MYNZ )

3.990 -0.680 (-14.56%)
Streaming Delayed Price Updated: 3:58 PM EST, Jan 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 50,222
Open 4.630
Bid (Size) 4.070 (1)
Ask (Size) 4.490 (8)
Prev. Close 4.670
Today's Range 3.990 - 4.635
52wk Range 0.1800 - 7.950
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Quest Diagnostics (NYSE: DGX) And Mainz Biomed (NASDAQ: MYNZ) Team Up To Commercialize ColoAlert Early Cancer Detection Screening In The U.S.
Quest Diagnostics (NYSE: DGX) And Mainz Biomed (NASDAQ: MYNZ) Team Up To Commercialize ColoAlert Early Cancer Detection Screening In The U.S. 
Via News Direct
Exposures Product Safety
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga

Performance

YTD
-7.21%
-7.21%
1 Month
-40.00%
-40.00%
3 Month
+960.32%
+960.32%
6 Month
+883.73%
+883.73%
1 Year
+262.73%
+262.73%

More News

Read More
Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Announces Reverse Stock Split Soon After Collaborating With MedTech Giant Thermo Fisher Scientific
Via Benzinga
Mainz Biomed Announces Stock Split
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Inks Major Deal To Develop A Next-Generation Cancer Test
Via News Direct
The Oncology Bet Is Already Paying Off For Pfizer
Via Benzinga
Exposures COVID-19
Healthcare Giant Thermo Fisher Scientific Inc. (NYSE: TMO) Inks Deal With Mainz Biomed (NASDAQ: MYNZ) To Develop And Commercialize Next Gen Colorectal Cancer Screening
Via News Direct
Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global Markets
From Mainz BioMed NV
Via GlobeNewswire
What Mainz Biomed (NASDAQ: MYNZ) Has Been Up To Recently And Why Frankie Muniz Is A Backer
Via News Direct
Exposures Product Safety
Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update
From Mainz BioMed NV
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Personalized Treatment And Immunotherapy Are Pharma's Newest Weapons Against Cancer
Via Benzinga
Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version
From Mainz BioMed NV
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Former Senior Advisor To Obama Joins Forces With Innovative Biotech To Catch Cancer Early
Via News Direct
The Covid Era Tech Promises To Reinvent Cancer Treatment
Via Benzinga
Exposures COVID-19
Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025
From Mainz BioMed NV
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Pfizer Advances On Its Cancer Journey
Via Benzinga
Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador
From Mainz BioMed NV
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.